Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Pulmonx Corporation (LUNG)

11.18   0.21 (1.91%) 03-31 16:00
Open: 11.05 Pre. Close: 10.97
High: 11.28 Low: 10.88
Volume: 671,091 Market Cap: 421(M)

Technical analysis

as of: 2023-03-31 4:20:17 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 13.88     One year: 14.92
Support: Support1: 10.43    Support2: 8.68
Resistance: Resistance1: 11.88    Resistance2: 12.77
Pivot: 11.36
Moving Average: MA(5): 10.94     MA(20): 11.38
MA(100): 8.55     MA(250): 14.45
MACD: MACD(12,26): 0.2     Signal(9): 0.3
Stochastic oscillator: %K(14,3): 25     %D(3): 19.1
RSI: RSI(14): 52.5
52-week: High: 28.29  Low: 4.07
Average Vol(K): 3-Month: 509 (K)  10-Days: 458 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ LUNG ] has closed above bottom band by 40.8%. Bollinger Bands are 43.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 11.29 - 11.34 11.34 - 11.38
Low: 10.77 - 10.82 10.82 - 10.87
Close: 11.1 - 11.18 11.18 - 11.26

Company Description

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Headline News

Thu, 16 Mar 2023
Pulmonx Co. (NASDAQ:LUNG) Receives Average Rating of ... - MarketBeat

Tue, 14 Mar 2023
50174 Shares in Pulmonx Co. (NASDAQ:LUNG) Acquired by ... - MarketBeat

Fri, 24 Feb 2023
Why Shares of Pulmonx Rose This Week - The Motley Fool

Wed, 22 Feb 2023
Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Wed, 22 Feb 2023
Pulmonx Reports Fourth Quarter and Full Year 2022 Financial Results - GlobeNewswire

Wed, 30 Nov 2022
Pulmonx Receives Japanese MHLW Approval of Zephyr ... - Business Wire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Medical Devices
Shares Out. 37 (M)
Shares Float 30 (M)
% Held by Insiders 3.6 (%)
% Held by Institutions 105.9 (%)
Shares Short 2,950 (K)
Shares Short P.Month 2,940 (K)

Stock Financials

EPS -2
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.11
Profit Margin (%) -111
Operating Margin (%) -108.6
Return on Assets (ttm) -15.7
Return on Equity (ttm) -31.5
Qtrly Rev. Growth 1.7
Gross Profit (p.s.) 0.95
Sales Per Share 1.38
EBITDA (p.s.) -1.47
Qtrly Earnings Growth 0
Operating Cash Flow -46 (M)
Levered Free Cash Flow -23 (M)

Stock Valuations

PE Ratio -5.6
PEG Ratio -0.3
Price to Book value 1.82
Price to Sales 8.05
Price to Cash Flow -9.1

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.